Market Cap: $7.3B
II
Ionis Pharmaceuticals, Inc.
IONS
NASDAQ (NASDAQ Global Select)USD
Market Cap: $7.3B
Ionis Pharmaceuticals, Inc. ( IONS ) is drawing attention as the latest developments come into focus. Ionis Pharmaceuticals, Inc. (IONS) currently stands at a significant crossroads in its operational…
Ionis Pharmaceuticals, Inc. IONS finds itself at a pivotal juncture, grappling with unexpected trial outcomes while simultaneously celebrating significant breakthroughs in drug development. The dynami…
Ionis Pharmaceuticals (Ticker: IONS) marks a pivotal moment in its growth with the recent FDA approval of Tryngolza (olezarsen), now recognized as the first drug specifically designed to lower triglyc…
Ionis Pharmaceuticals (Ticker: IONS) shares promising long-term data on its RNA therapy olezarsen, designed to treat severe hypertriglyceridemia. The recent findings from an ongoing extension study hi…
Ionis Pharmaceuticals (Ticker: IONS) presents promising new clinical data on its triglyceride drug candidate, olezarsen, during the recent National Lipid Association Scientific Sessions. The company r…
Ionis Pharmaceuticals (Ticker: IONS) has recently appointed Ludwig Hantson, Ph.D., to its Board of Directors, marking a significant step in the company’s ongoing strategy to advance its innovative RNA…
Ionis Pharmaceuticals (Ticker: IONS) has recently made significant advancements in its antisense pipeline, particularly with the latest Phase 3 data for olezarsen, aiming to target severe hypertriglyc…
Ionis Pharmaceuticals (Ticker: IONS) makes significant strides with its antisense therapy pipeline, positioning itself as a leader in addressing critical health disorders. Recent positive results from…
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…
Regulatory Challenges in Gene Therapy Development: A Focus on UniQure and Implications for the Industry The ongoing scrutiny faced by UniQure's gene therapy for Huntington's disease exemplifies the ch…
UniQure's Gene Therapy for Huntington's Disease Under Fire: A Regulatory Standoff UniQure faces heightened scrutiny from the U.S. Food and Drug Administration (FDA) for its gene therapy targeting Hunt…
Ionis Pharmaceuticals: Navigating the Complex Landscape of RNA-targeted Therapies Ionis Pharmaceuticals finds itself at a pivotal moment, with a recently observed interest from six analysts regarding…
Ionis Pharmaceuticals Shows Resilience with Better-than-Expected Q4 Results Ionis Pharmaceuticals Inc. highlights its financial resilience through the release of its fourth-quarter earnings, demonstra…
Ionis Pharmaceuticals: A Resilient Leader in RNA-Targeted Therapies Ionis Pharmaceuticals Inc. has demonstrated a remarkable ability to navigate financial challenges, recently reporting an adjusted lo…
Ionis Pharmaceuticals: Pioneering Advances in RNA Therapeutics Ionis Pharmaceuticals stands at the forefront of innovation in the biopharmaceutical industry, particularly in the development of RNA-tar…
Ionis Pharmaceuticals Sees Notable Shift in Investor Sentiment Ionis Pharmaceuticals Inc. is currently experiencing a significant decline in its short interest, with a reported 9.47% decrease since th…
Deucrictibant Shows Promise in Phase 3 Trial for HAE: Implications for the Rare Disease Treatment Landscape Pharvaris N.V. achieves a significant milestone with the topline results from its RAPIDe-3 P…
Deucrictibant Emerges as a Potential Breakthrough in Hereditary Angioedema Treatment Pharvaris N.V. announces promising topline results from its RAPIDe-3 Phase 3 trial, assessing the effectiveness of…
Ionis Pharmaceuticals Advances in Treatment for Severe Hypertriglyceridemia Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has recently spotlighted its pioneering efforts in treating severe hypertriglyceri…
Ionis Pharmaceuticals Advances in Lipid Disorder Treatment with Olezarsen Trials Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) makes significant strides in the treatment of severe hypertriglyceridemia (sH…
Ionis Pharmaceuticals: Innovations in RNA Therapeutics Ionis Pharmaceuticals stands at the forefront of the biotechnology sector, specifically in the realm of RNA-targeted therapeutics. The company fo…
Exact Sciences Prepares for Earnings Announcement Amidst Industry Challenges Exact Sciences, a leader in cancer screening and diagnostic solutions, is poised to unveil its quarterly earnings on Novemb…
Ionis Pharmaceuticals: Advancing Innovation in Genetic Medicine Ionis Pharmaceuticals stands at the forefront of innovation in the biotechnology sector, particularly in the realm of genetic medicine.…
Ionis Pharmaceuticals Gears Up for Quarterly Earnings: A Focus on Advancements in RNA-Targeted Therapies Ionis Pharmaceuticals prepares to unveil its quarterly earnings report on October 29, 2025, a m…
Ionis Pharmaceuticals: Advancing Rare Disease Treatment through Innovation Ionis Pharmaceuticals stands at the forefront of the biopharmaceutical industry, particularly in the development of therapies…